Contribute Try STAT+ Today

Exact Sciences announced Tuesday it had acquired Thrive Earlier Detection, a liquid biopsy company that launched last year with technology from Johns Hopkins University, for $2.15 billion.

The acquisition is yet another boon for the liquid biopsy industry, which has matured in the last five years from “the long-sought holy grail of oncology” to a concept with concrete data behind it. This is the second acquisition this year of a liquid biopsy company developing tests for healthy people; the major DNA sequencing machine maker Illumina bought Grail for $8 billion in cash and stock in September.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.